The question of whether selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy are a hidden cause of autism is complex and remains an area of active research and debate. Current authoritative evidence does not conclusively establish SSRIs as a direct cause of autism, but some studies suggest a possible association that requires careful interpretation.
SSRIs are a class of antidepressants commonly prescribed to treat depression and anxiety, including during pregnancy. Untreated maternal depression itself poses significant risks to both mother and fetus, such as preterm birth, preeclampsia, impaired mother-infant bonding, and even maternal suicide, which can have severe consequences for child development[4][5]. Therefore, the decision to use SSRIs during pregnancy involves weighing the benefits of treating maternal mental health against potential risks to the fetus.
Several large, well-controlled epidemiological studies have observed that children exposed to SSRIs in utero may have a slightly increased risk of being diagnosed with autism spectrum disorder (ASD) compared to children of mothers with mental illness who did not take SSRIs[1]. For example, a study published in the BMJ found increased autism rates in children exposed to antidepressants during pregnancy compared to children of women with psychiatric diagnoses who did not use these medications[1]. However, these findings are complicated by confounding factors such as the genetic and environmental influences of maternal mental illness itself, which is also linked to autism risk.
Animal studies provide additional evidence that SSRIs can affect neurodevelopment. Research shows that maternal SSRI exposure reduces social interactions, play behavior, and exploratory activity in offspring, which are behaviors relevant to autism[1]. These findings suggest a potential drug-related effect on brain development, but translating animal model results to humans requires caution.
A key biological mechanism involves serotonin, a neurotransmitter critical for brain development. Recent research from Yale University has shown that the placenta regulates serotonin delivery to the fetus rather than producing it independently[2][5]. SSRIs alter serotonin levels by blocking its reuptake, which can affect the amount of serotonin reaching the fetus. This “serotonin shield” function of the placenta means that SSRIs could influence fetal brain development by modifying serotonin transport. Interestingly, both too little and too much serotonin exposure may have developmental consequences: low serotonin is linked to smaller babies, while increased serotonin may be associated with larger babies and potentially higher autism risk[2][5].
Despite these concerns, major medical organizations such as the American College of Obstetricians and Gynecologists (ACOG) and experts in maternal-fetal medicine emphasize that SSRIs are generally safe during pregnancy and that the risks of untreated maternal depression often outweigh the potential risks of medication[4][5]. The FDA convened a panel in 2025 to discuss SSRI use in pregnancy, during which some panelists made inaccurate claims linking SSRIs to fetal alcohol syndrome and autism, which have been debunked by scientific consensus[3]. Experts caution against misinformation that may deter pregnant individuals from receiving necessary treatment.
In summary, while some epidemiological and animal studies suggest a possible association between prenatal SSRI exposure and autism, the evidence is not definitive and is confounded by maternal mental health factors. The placenta’s role in regulating fetal serotonin exposure provides a plausible biological pathway but also highlights the complexity of neurodevelopment. Current authoritative guidance supports the use of SSRIs during pregnancy when clinically indicated, emphasizing the importance of treating maternal depression to protect both maternal and child health[4][5][6].
—
